Attention is focusing on whether Vabysmo, a macular degeneration treatment, will be able to be listed on the insurance benefit list. According to related industries, it is expected that Vabysmo, a Bispecific antibody treatment in Roche Korea, will be presented to the Drug Benefit Evaluation Committee this month (July). This drug passed the Drug Benefit Standards Subcommittee in May.

Vabysmo, licensed as a treatment for neovascular or wet-related macular degeneration (nAMD) and vision damage by diabetic macular edema, is a new drug with a differentiated mechanism that targets both VEGF-A and Ang-2, the main path of disease. Based on the new mechanism, it is the first intraocular injection that enables ad